U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07572006) titled 'A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies' on April 30.
Brief Summary: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose [RP2D]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the ...